Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: A randomized cross-over study

Diabetes Care

Volumn 34, Issue 6, 2011, Pages 1312-1314

  Lucidi, Paola ^a   Porcellati, Francesca ^a   Rossetti, Paolo ^a   Candeloro, Paola ^a   Cioli, Patrizia ^a   Marzotti, Stefania ^a   Andreoli, Anna Marinelli ^a   Fede, Raffaela ^a   Bolli, Geremia B ^a   Fanelli, Carmine G ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; C PEPTIDE; FATTY ACID; GLUCAGON; GLYCEROL; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN;

ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG METABOLISM; DRUG WITHDRAWAL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HUMAN; INFUSION RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE;

BLOOD GLUCOSE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; INSULIN; INSULIN, NPH;

EID: 80052003991     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1911     Document Type: Article

References (10)

1. Hompesch M., Troupin B., Heise T., et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab 2006;8:568-573 (Pubitemid 44184251)
2. Linn T., Fischer B., Soydan N., et al. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:3839-3846
3. Porcellati F., Rossetti P., Busciantella N.R., et al. Comparison of pharmacokinetics and dynamics of the Long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: A double-blind, randomized, crossover study. Diabetes Care 2007;30:2447-2452 (Pubitemid 47547770)
4. Lucidi P., Rossetti P., Porcellati F., et al. Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: The role of lipolysis. Diabetes 2010;59:1349-1357
5. Gastaldelli A., Coggan A.R., Wolfe R.R. Assessment of methods for improving tracer estimation of non-steady-state rate of appearance. J Appl Physiol 1999;87:1813-1822
6. Senn S. Normal data from designs with three or more treatments. In Cross-Over Trials in Clinical Research. 2nd ed. New York, John Wiley & Sons, 2002, p. 157-182
7. Owens D.R., Bolli G.B. Beyond the era of NPH insulin: long-acting insulin analogs: Long-acting insulin analogsChemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008;10:333-349
8. Bolli G.B., Gerich J.E. The "dawn phenomenon": A common occurrence in both noninsulin- dependent and insulin-dependent diabetes mellitus. N Engl JMed 1984;310:746-750 (Pubitemid 14161406)
9. Boden G., Chen X., Urbain J.L. Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production. Diabetes 1996;45:1044-1050 (Pubitemid 26260156)
10. Rosenstock J., Davies M., Home P.D., Larsen J., Koenen C., Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-416